Cite
HARVARD Citation
Vlasakakis, G. et al. (2019). Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients. British journal of clinical pharmacology. 85 (4), pp. 704-714. [Online].